Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regenxbio (RGNX) Cash & Current Investments (2016 - 2025)

Regenxbio (RGNX) has 12 years of Cash & Current Investments data on record, last reported at $230.1 million in Q4 2025.

  • For Q4 2025, Cash & Current Investments fell 1.97% year-over-year to $230.1 million; the TTM value through Dec 2025 reached $230.1 million, down 1.97%, while the annual FY2025 figure was $230.1 million, 1.97% down from the prior year.
  • Cash & Current Investments reached $230.1 million in Q4 2025 per RGNX's latest filing, down from $274.2 million in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $457.4 million in Q4 2021 and bottomed at $230.1 million in Q4 2025.
  • Average Cash & Current Investments over 5 years is $330.0 million, with a median of $327.6 million recorded in 2023.
  • Peak YoY movement for Cash & Current Investments: skyrocketed 57.88% in 2021, then dropped 24.51% in 2023.
  • A 5-year view of Cash & Current Investments shows it stood at $457.4 million in 2021, then fell by 20.29% to $364.6 million in 2022, then decreased by 24.51% to $275.3 million in 2023, then fell by 14.74% to $234.7 million in 2024, then decreased by 1.97% to $230.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Current Investments were $230.1 million in Q4 2025, $274.2 million in Q3 2025, and $323.3 million in Q2 2025.